logo
These Are the 4 Most Unfriendly Myers-Briggs Personality Types, According to a Psychotherapist

These Are the 4 Most Unfriendly Myers-Briggs Personality Types, According to a Psychotherapist

Yahoo10 hours ago
These Are the 4 Most Unfriendly Myers-Briggs Personality Types, According to a Psychotherapist originally appeared on Parade.
Everybody's different, and we've all had our own unique experiences in life that have shaped us. In the intricate tapestry of human personalities, the Myers-Briggs Type Indicator (MBTI) stands out as one of the most renowned and widely used personality assessment tools. The MBTI identifies individuals' preferences across four areas: extraversion (E) vs. introversion (I), sensing (S) vs. intuition (N), thinking (T) vs. feeling (F) and judging (J) vs. perceiving (P), resulting in 16 personality types. It ultimately indicates differing psychological preferences in how people perceive the world and make decisions.While each Myers-Briggs personality type carries its unique strengths and charms, some personalities have been perceived as less friendly than others. Mayya Fleyshmakher, MA, LPC, is a licensed clinical psychotherapist who utilizes the MBTI in her own private practice to help clients with their career choices and advancements as they progress. Here, she offers her expert insight to answer the ultimate question: what are the most unfriendly Myers-Briggs personality types? The answers may surprise you!Related:
There is no singular Myers-Briggs personality type that can be drawn as the most unfriendly of them all. However, particular dichotomies of these differing types may make them seem more unfriendly than others. Fleyshmakher tells Parade, "The 'Thinking' (T) types might be more prone to exhibit cold or detached behavior due to their focus on logic and objectivity over emotional considerations." She continues, "They may lack empathy, therefore portraying signs of misattunement, appearing to be unfriendly and even selfish." These "Thinking" types that may seem more unfriendly include INTJ, INTP, ENTJ and ENTP. And out of all the types to be considered the most unfriendly Myers-Briggs personality types, Fleyshmakher says that the INTJ seems to face more isolating behaviors due to introverted tendencies. This often leads them to be more reserved and less empathetic towards others. So, if you're friends with one of these "Thinking" Myers-Briggs types, try to keep in mind that they are not purposely being unfriendly. These personality types tend to lean on facts and logic over acting on emotion. "It's crucial to remember that such traits do not necessarily indicate hostility or unkindness; rather, they reflect a different approach to processing and expressing emotions. When factoring in trauma, you might even meet 'Thinking' types who utilize this personality trait to bypass dealing with complex emotions, often resorting to numbing responses," Fleyshmakher explains.Related:
The most important consideration to remember when utilizing the MBTI is that no personality type is inherently unfriendly. People are complex and unique beings, and it's imperative that the role of individual trauma is not overlooked. "Determining more or less 'friendlier' types of the MBTI requires consideration as to how trauma affects these personality traits in the first place," Fleyshmakher explains. Our society has long associated the word "trauma" with intense experiences, like abuse and war combat. However, the updated definition of trauma is generally understood as an emotional response to a distressing or disturbing event(s) that overwhelms an individual's ability to cope. Fleyshmakher adds, "Considering how we now define trauma, more and more individuals report that they have experienced some level of trauma in their lifetime." She continues, "The Myers-Briggs and its types present limitations, as it does not set out to factor the role of trauma on personality."
As with any tool similar to the MBTI, it's not a one-size-fits-all and must be carefully reviewed, relative to each person. When considering individualized trauma and the use of the MBTI, some trauma responses may mimic the Myers-Briggs personality features. "Individuals with trauma symptoms exhibit hyper-independence, overthinking and mistrust. Many of my clients are shocked to find out that what they thought was part of their personalities turned out to be symptoms, which quickly changed once they completed trauma work." Fleyshmakher adds, "Therefore, what may seem as the unfriendly, introverted types of the MBTI are really just the symptoms of difficult childhoods and stress."Related:
Contrasting their highly logical counterparts, the "Feeling" (F) types tend to prioritize empathy and emotions in their decision-making process, often leading to a more friendly demeanor. These more friendly Myers-Briggs personality types include INFJ, INFP, ENFJ and ENFP."The ability to display empathy is a key factor in fostering healthy platonic and romantic relationships and, overall, 'Feeling' types come off as the friendlier types of the Myers-Briggs," Fleyshmakher shares. "Individuals who struggle in finding the right partner often overlook prioritizing empathy as above looks or status. These types might find more success in looking to formulate relationships with 'Feeling' types."Fleyshmakher tells Parade that she often shies away from creating rigid definitions of personality because there is usually always more work lying beneath the surface. She touches upon her own experience from a psychotherapist's lens: "I have met many 'Feeling' types who fall under the ENFP types that, upon doing deeper work in therapy, learned their complacent and often lovable, friendly demeanor was a learned behavior from childhood, specifically in learning to survive with abrasive, volatile and harsh parents." Related:
Overall, the MBTI can provide insight into an individual's preferences and tendencies. It shows differing psychological preferences in how people perceive the world and make decisions. However, the MBTI should not be used as a definitive assessment of personality or as the sole basis for therapeutic interventions.In her own private practice, Fleyshmakher uses the MBTI to help clients with their career choices and advancements—with the important caveat that it is only utilized once a client has completed the appropriate clinical interventions to help them process and heal trauma. Thus, therapists may use the MBTI to better understand a client's communication style, decision-making processes and coping mechanisms. But, considering individualized trauma and responses will allow for a more accurate reading of the Myers-Briggs assessment.Related:
Due to its popularity, there are many variations of the MBTI test online. However, the original assessment, which is still utilized by certified practitioners, is considered the most accurate, as it involves a structured and methodical approach.
The Myers-Briggs Type Indicator (MBTI) was first developed by Katharine Cook Briggs and her daughter Isabel Briggs Myers. The assessment was based heavily on Carl Jung's theory of psychological types.
Up Next:Mayya Fleyshmakher, MA, LPC, is a licensed clinical psychotherapist in private practice in Holmdel, New Jersey. Fleyshmakher specializes in trauma-focused EMDR Therapy and spreading awareness about the importance of trauma work, specifically in educating people about how they perceive, define and treat trauma.You can connect with Mayya here:
Website
Instagram
TikTok
These Are the 4 Most Unfriendly Myers-Briggs Personality Types, According to a Psychotherapist first appeared on Parade on Jul 2, 2025
This story was originally reported by Parade on Jul 2, 2025, where it first appeared.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Yahoo

time34 minutes ago

  • Yahoo

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising future in the market. 10 stocks we like better than Eli Lilly › Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for explosive growth. And today, the perfect example is weight loss drugs. Today's $28 billion weight loss drug market is on track to reach nearly $100 billion by 2030, according to Goldman Sachs Research, offering companies in the space an extremely solid opportunity over the next several years and likely beyond. Two names that have been making headlines in this field are Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX). The former is a current leader, already selling two blockbuster drugs prescribed for weight loss, and the latter is an up-and-coming player, with a candidate in late-stage trials. Which is the better growth buy today? Let's find out. Eli Lilly shares weight loss drug market leadership with fellow big pharma player Novo Nordisk. They each commercialize two drugs prescribed to people aiming to lose weight and have brought in billions of dollars in annual revenue. Here, I'll focus on Lilly. The company's drugs, Mounjaro and Zepbound, are actually the same compound, tirzepatide. But it's sold under the name Mounjaro for type 2 diabetes and under the name Zepbound for weight loss. The drug acts by stimulating hormonal pathways involved in the control of blood sugar levels and appetite. Thanks to the efficacy of tirzepatide, demand has soared, even surpassing supply until Lilly expanded its production capacity. But Lilly isn't sitting still in the area of weight loss. The company also is developing other drug candidates that may improve upon tirzepatide. The closest to market right now is orforglipron, Lilly's oral candidate for weight loss that recently delivered positive phase 3 trial results. If approved, it would be the only oral weight loss drug of its class that doesn't require strict food and water restrictions. Lilly aims on applying for regulatory review by the end of this year. All of this could result in more growth for Lilly this year and well into the future. Viking Therapeutics is a biotech company specializing in metabolic conditions, and it's made great progress with its obesity drug candidate, VK2735. The potential drug, in subcutaneous form, recently entered a phase 3 trial, and an oral form is involved in a phase 2 trial. These candidates are in the same class as tirzepatide, so work in the same way. Investors have shown their excitement about Viking's program in the past: When the company reported positive phase 2 data for the subcutaneous VK2735 last year, the stock soared more than 120% in one trading session. The stock hasn't maintained those gains, but the movement shows that investors are interested in the program -- and more good news ahead could boost the stock again. Now you might wonder why investors are so excited about Viking if there already are other successful weight loss drugs on the market -- and Lilly even is likely to reach commercialization with an oral weight loss drug ahead of Viking. This is because demand is high, and this is set to continue, so there is plenty of room for more than a couple of companies to succeed in the space. Investors also have speculated about the idea of a big pharma company acquiring Viking to get in on this high growth market. Lilly has the first-to-market advantage, is closer to the finish line with an oral candidate, and already is generating major revenue from its weight loss portfolio. Viking, if successful through clinical trials, could carve out market share and deliver major revenue growth down the road -- or the company could be acquired, offering investors another way to potentially gain. Each company offers certain advantages. Now let's answer our question. If all goes well for Viking, it could represent the better growth buy as, starting from zero product revenue today, this player could see revenue soar if and when it brings a weight loss drug to market. And we've seen that Viking's stock price is very reactive to news, meaning the stock could skyrocket in such a scenario. But, if you go the Viking route, you should be comfortable with risk as uncertainty remains: The company hasn't yet reached the finish line with a product. If you're more of a cautious investor, though, don't worry. You may opt for Lilly as, even though it's climbed 140% over the past three years, it still could have plenty of room to run over the long term thanks to this weight loss drug growth story. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Better Growth Buy: Eli Lilly vs. Viking Therapeutics was originally published by The Motley Fool

3 Cash-Heavy Stocks Worth Investigating
3 Cash-Heavy Stocks Worth Investigating

Yahoo

time34 minutes ago

  • Yahoo

3 Cash-Heavy Stocks Worth Investigating

A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital. Not all companies with sound capital structures are created equal, and StockStory is here to help you find the best. Keeping that in mind, here are three companies with net cash positions that can continue growing sustainably. Net Cash Position: $76.13 million (4.4% of Market Cap) Founded in 1987, American Superconductor (NASDAQ:AMSC) has shifted from superconductor research to developing power systems, adapting to changing energy grid needs and naval technology requirements. Why Are We Bullish on AMSC? Impressive 45% annual revenue growth over the last two years indicates it's winning market share this cycle Free cash flow margin is now positive, showing the company is at an important crossroads Improving returns on capital suggest its past investments are beginning to deliver value American Superconductor's stock price of $39.39 implies a valuation ratio of 75.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Net Cash Position: $259.3 million (2.4% of Market Cap) Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Why Is HIMS a Good Business? Average customer growth of 48.6% over the past two years demonstrates success in acquiring new clients that could increase their spending in the future Earnings per share have massively outperformed its peers over the last four years, increasing by 37% annually Free cash flow margin grew by 23.5 percentage points over the last five years, giving the company more chips to play with At $47.98 per share, Hims & Hers Health trades at 36.3x forward EV-to-EBITDA. Is now the right time to buy? See for yourself in our full research report, it's free. Net Cash Position: $299.7 million (9.4% of Market Cap) Founded in 2013 as a champion for content creator rights and free expression, Rumble (NASDAQ:RUM) is a video sharing platform that positions itself as a free speech alternative to mainstream platforms, offering creators more favorable revenue-sharing opportunities. Why Could RUM Be a Winner? Impressive 38.4% annual revenue growth over the last two years indicates it's winning market share this cycle Rumble is trading at $9.35 per share, or 21.9x trailing 12-month price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs
Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs

Yahoo

timean hour ago

  • Yahoo

Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs

Schizophrenia Drugs Market Dublin, July 07, 2025 (GLOBE NEWSWIRE) -- The "Schizophrenia Drugs Market Size, Share & Trends Analysis by Drug Class (Second- Generation Antipsychotics, Third-Generation Antipsychotics), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030" report has been added to Schizophrenia Drugs Market was valued at USD 8.19 billion in 2024, and is projected to reach USD 11.20 billion by 2030, rising at a CAGR of 5.60%. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating Drugs Market Report Highlights The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics. The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications. The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition. North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes Report Attribute Details No. of Pages 100 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $8.19 Billion Forecasted Market Value (USD) by 2030 $11.2 Billion Compound Annual Growth Rate 5.6% Regions Covered Global Key Topics CoveredChapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Drug Class and Route of Administration Outlook2.2.2. Distribution Channel Outlook2.2.3. Regional Outlook2.3. Competitive InsightsChapter 3. Schizophrenia Drugs Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent Market Outlook3.1.2. Related/Ancillary Market Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Schizophrenia Drugs Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.1.1. Supplier Power3.3.1.2. Buyer Power3.3.1.3. Substitution Threat3.3.1.4. Threat of New Entrant3.3.1.5. Competitive Rivalry3.3.2. PESTEL Analysis3.3.2.1. Political Landscape3.3.2.2. Technological Landscape3.3.2.3. Economic Landscape3.3.3. Pricing Analysis3.3.4. Pipeline Analysis3.3.4.1. Phase 13.3.4.2. Phase 23.3.4.3. Phase 3Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis4.3. Global Schizophrenia Drugs Market by Class, Revenue4.4. Second-Generation Antipsychotics4.5. Third-Generation Antipsychotics Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue5.4. Oral Antipsychotics5.5. Injectable Antipsychotics Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue6.4. Hospital Pharmacies6.5. Retail Pharmacies6.6. Online Pharmacies6.7. Others Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration7.1. Regional Dashboard7.2. Market Size, & Forecasts Trend Analysis, 2018 to 20307.3. North America7.4. Europe7.5. Asia-Pacific7.6. Latin America7.7. MEA Chapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, by Key Market Participants8.2. Company/Competition Categorization8.3. Vendor Landscape8.3.1. List of Key Distributors and Channel Partners8.3.2. Key Customers8.3.3. Key Company Market Share Analysis, 20248.3.4. Johnson & Johnson Services, Inc.8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.8.3.6. Sumitomo Pharma Co., Ltd.8.3.7. Eli Lilly and Company8.3.8. Alkermes8.3.9. VANDA PHARMACEUTICALS8.3.10. AstraZeneca8.3.11. AbbVie Inc.8.3.12. Pfizer Inc.8.3.13. H. Lundbeck A/S For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Schizophrenia Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store